Recent Updates
Recently added Catalysts

AGN-190584

Phase 3

Presbyopia | Small molecule | Ophthalmology |AbbVie Inc.|Last Updated: Oct 10, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment43

FDA Designations

No designations recorded

Clinical trial landscape

AGN-190584 · 1 trial · 1 indication

Phase 3 1
NCT04837482A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of AgePresbyopia
COMPLETED43 Analytics
PHASE3COMPLETED
A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age
PresbyopiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Overall Composite Driving Z Score Approximately 1 Hour After Study Intervention Instillation
One hour after study intervention instillation at Visit 3 (Day 8 to 15) and at Visit 5 (Day 22 to 71)

An overall composite driving Z-score approximately 1 hour after study intervention instillation was derived to capture the overall driving performance of each participant compared with the whole group for the following parameters: percent hazards hit, percent sign recognition and recognition distance, pedestrian recognition distances, and percent of time outside of the lane. For each participant, the Z-score for each task of the driving test was the difference between his/her value and mean value of the assessments of all participants from the pooled data of both periods combined, divided by the standard deviation of all corresponding assessment values. Because a lower percentage of hazards hit, lower percentage of time outside of the driving lane, and a shorter lap duration indicate better driving performance, the Z-scores of these components were reversed (multiplied by -1) before computing the overall composite driving Z-score. A higher Z-score indicates better driving performance.

Number of Participants With Adverse Events
Enrollment to Day 71

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The investigator assesses the relationship of each event to the use of the study intervention. A serious adverse event (SAE) is an event that results in death, is life threatening, requires inpatient hospitalization or prolongs an existing hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event, that based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
AGN-190584 Sequence 1EXPERIMENTALAGN-190584 Sequence 1 (Participants will receive AGN-190584 from Visit 2 through Visit 3 followed by Vehicle from Visit 4 through Visit 5).
AGN-190584 Sequence 2EXPERIMENTALAGN-190584 Sequence 2 (Participants will receive Vehicle from Visit 2 through Visit 3 followed by AGN-190584 from Visit 4 through Visit 5).

Interventions

NameTypeDescription
AGN-190584DRUGTopical eyedrop
VehicleDRUGTopical eyedrop
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 55 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * In good general health at the screening visit, as determined by the investigator from medical history. * Subjective complaints of poor near vision that impacts activities of daily living, as defined by at least a moderate impact (score \> = 3) on at least 1 question on NEI VFQ...

Countries:Australia
Unlock Eligibility Criteria

Frequently asked questions about AGN-190584

What is AGN-190584 used for?

AGN-190584 is an investigational small molecule being developed for presbyopia, an age-related eye condition that reduces the ability to focus on close objects. It is administered as a topical eyedrop. The drug is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.

Who makes AGN-190584?

AGN-190584 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of presbyopia.

What phase is AGN-190584 in?

AGN-190584 is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies such as the FDA. The drug is being studied for the treatment of presbyopia, with clinical trials currently completed.

What clinical trials is AGN-190584 in?

AGN-190584 has one completed Phase 3 clinical trial registered under NCT04837482. This study assessed the impact and adverse events of topical eyedrops of AGN-190584 on night-driving performance in participants aged 40 to 55 years with presbyopia. The trial was conducted in Australia and enrolled 43 participants.

Is AGN-190584 the same as any other drug?

No alternative names for AGN-190584 have been disclosed. The drug is identified solely by its development code AGN-190584 and is being investigated by AbbVie for the treatment of presbyopia.